Skip to content

Research and development of immune intervention treatment decision-making system for

Research and development of immune intervention treatment decision-making system for sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071882
Enrollment
Unknown
Registered
2023-05-29
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

intervention group:Starting from the day of enrollment, 1.6mg thymosin (Lidaxian) was subcutaneously injected q12h for a course of 7 days
control group:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: When patients meet all the following conditions, they can choose to enter the study: (1) Age 18 years or older; (2) Conforming to the 2016 American Society of Critical Care Medicine/European Society of Critical Care Medicine (SCCM/ESICM) Sepsis 3.0 definition criteria for sepsis, that is, fatal organ dysfunction caused by infection (Sequential (Infection related) organ failure score SOFA = 2), or the need for vasopressor drugs to maintain mean arterial pressure = 65mmHg and blood lactate level>2mmol/L after sufficient fluid resuscitation; (3) Lymphocyte count<1.0 × 10^9/L; (4) The patient or family member is able to understand the research protocol and is willing to participate in this study, providing written informed consent.

Exclusion criteria

Exclusion criteria: Complies with any one of the following (1) Age<18 years old; (2) Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
28-day mortality;

Countries

China

Contacts

Public ContactNa Cui

Peking Union Medical College Hospital

pumchcn@163.com+86 156 0121 2623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026